Search research articles
Contact Us
Filters
Showing results (21-30 of 102) with videos related to
Page
of 11
Sort By:
Molecular Cancer Therapeutics
|
October 28, 2003
Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B
Lianne Fuino, Purva Bali, Sylvie Wittmann, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
April 10, 2013
Acetylated hsp70 and KAP1-mediated Vps34 SUMOylation is required for autophagosome creation in autophagy
Yonghua Yang, Warren Fiskus, Bao Yong, et al.
Molecular Pharmacology
|
September 29, 2005
The histone deacetylase inhibitor LAQ824 induces human leukemia cell death through a process involving XIAP down-regulation, oxidative injury, and the acid sphingomyelinase-dependent generation of ceramide
Roberto R Rosato, Sonia C Maggio, Jorge A Almenara, et al.
Cancer Research
|
April 3, 2004
Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells
Fei Guo, Celia Sigua, Jianguo Tao, et al.
Cancer Research
|
September 5, 2006
Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha
David Z Qian, Sushant K Kachhap, Spencer J Collis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 4, 2008
Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors
Henk M W Verheul, Brenda Salumbides, Karen Van Erp, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 11, 2009
High efficacy of panobinostat towards human gastrointestinal stromal tumors in a xenograft mouse model
Giuseppe Floris, Maria Debiec-Rychter, Raf Sciot, et al.
Blood
|
July 2, 2008
HDAC6 inhibition enhances 17-AAG--mediated abrogation of hsp90 chaperone function in human leukemia cells
Rekha Rao, Warren Fiskus, Yonghua Yang, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
February 21, 2012
Biocatalytic synthesis and structure elucidation of cyclized metabolites of the deacetylase inhibitor panobinostat (LBH589)
Andreas Fredenhagen, Matthias Kittelmann, Lukas Oberer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 24, 2006
Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589
David Z Qian, Yukihiko Kato, Shabana Shabbeer, et al.
Page
of 11
Search research articles
Search
Showing results (21-30 of 102) with videos related to
Sort By:
Page
of 11
Molecular Cancer Therapeutics
|
October 28, 2003
Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B
Lianne Fuino, Purva Bali, Sylvie Wittmann, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
April 10, 2013
Acetylated hsp70 and KAP1-mediated Vps34 SUMOylation is required for autophagosome creation in autophagy
Yonghua Yang, Warren Fiskus, Bao Yong, et al.
Molecular Pharmacology
|
September 29, 2005
The histone deacetylase inhibitor LAQ824 induces human leukemia cell death through a process involving XIAP down-regulation, oxidative injury, and the acid sphingomyelinase-dependent generation of ceramide
Roberto R Rosato, Sonia C Maggio, Jorge A Almenara, et al.
Cancer Research
|
April 3, 2004
Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells
Fei Guo, Celia Sigua, Jianguo Tao, et al.
Cancer Research
|
September 5, 2006
Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha
David Z Qian, Sushant K Kachhap, Spencer J Collis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 4, 2008
Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors
Henk M W Verheul, Brenda Salumbides, Karen Van Erp, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 11, 2009
High efficacy of panobinostat towards human gastrointestinal stromal tumors in a xenograft mouse model
Giuseppe Floris, Maria Debiec-Rychter, Raf Sciot, et al.
Blood
|
July 2, 2008
HDAC6 inhibition enhances 17-AAG--mediated abrogation of hsp90 chaperone function in human leukemia cells
Rekha Rao, Warren Fiskus, Yonghua Yang, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
February 21, 2012
Biocatalytic synthesis and structure elucidation of cyclized metabolites of the deacetylase inhibitor panobinostat (LBH589)
Andreas Fredenhagen, Matthias Kittelmann, Lukas Oberer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 24, 2006
Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589
David Z Qian, Yukihiko Kato, Shabana Shabbeer, et al.
Page
of 11